natgillin/translations-raw huggingface dataset:
The antibody or antigen-binding fragment of claim 14 for use in treating osteopenia, osteoporosis, a fracture, achondroplasia, cleidrocranial dysostosis, echondromatosis, fibrous dysplasia, Gaucher's Disease, hypophoshatemic rickets, Marfan's syndrome, multiple hereditary exotoses, neurofibromatosis, osteogenesis inperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, peridontal disease, pseudoarthosis or pyogenic osteolmyelitis. 
Antitijelo ili njegov fragment koji se veže na antigen prema zahtjevu 13, naznačen time da se koristi za u liječenju osteopenije, osteoporoze, prijeloma, ahondroplazije, kleidrokranialne dizostose, enhondromatoze, fibrozne displazije, Gaucher-ove bolesti, hipofosfatemičnog rahitisa, Marfanova sindroma, multiple nasljedne egzotoze, neurofibromatoze, osteogeneze imperfekte, osteoporoze, osteopoikiloze, sklerotičnih lezija, parodontalnih bolesti, pseudoartroze ili piogeničnog osteomijelitisa.
The compound, pharmaceutically acceptable salt thereof or composition of Claim 8, for administration with a second therapeutic agent selected from a second HIV protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, a nucleoside/nucleotide reverse transcriptase inhibitor, a viral entry inhibitor, an integrase inhibitor, an immune based antiretroviral agent, a viral maturation inhibitor, a cellular inhibitor, and combinations of two or more of the above. 
Spoj ili kompozicija prema zahtjevu 15 za davanje s drugim terapeutskim sredstvom koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozidnog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaska virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili kombinacija dva ili više gore navedenih.
Typically, the total amount of the at least one hydrophobizing agent and/or at least one hydrophilizing agents will be from 0.1 to 10 wt %, preferably 0.2 to 5 wt %, more preferably 0.3 to 2.4 wt %, most preferably 0.4 to 1.9 wt %, especially 0.5 to 1.5 wt %, based on the weight of the hedgehog shaped particles. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da je barem jedno sredstvo za hidrofobiziranje, ili barem jedno sredstvo za hidrofiliranje, ili njihova smjesa prisutna u količini od 0.1 do 10 tež%, poželjno 0.2 do 5 tež%, poželjnije 0.3 do 2.4 tež%, najpoželjnije 0.4 do 1.9 tež%, naročito 0.5 do 1.5 tež%, bazirano na težini igličastih čestica.
The method according to claim 1, wherein the assembling comprises gluing of the sole to the upper assembly by adhesion, so as to form a waterproof seal, to the second gasket. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da navedena faza montaže (104) obuhvaća lijepljenje navedenog đona (20) na navedeni sklop gornjišta (11) prianjanjem na navedenu drugu brtvu (19) radi dobivanja vodonepropusnog spoja.
The radio communication apparatus according to claim 1, wherein the circuitry, in operation, calculates the sequence number by hopping a sequence number that is used in CoMP sets in a cell, wherein each of the CoMP sets comprises a plurality of base stations or cells performing communication with a radio communication apparatus in the coordinated manner, when the CoMP mode is set. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 2, naznačen time da je CoMP set konfiguriran od strane svih ćelija koje konfiguriraju CoMP setove kojima pripada pluralitet CoMP terminala prisutnih u ćelijama.
They are particularly suitable for the treatment of inflammatory, allergic and autoimmune disorders, such as asthma and chronic bronchitis, allergic, vasomotor and viral rhinitis, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, chronic inflammatory diseases of the bowel (Crohn's disease and ulcerative colitis), glomerulonephritis, psoriasis, rash, acute and chronic cystitis, hepatic cirrhosis, glomerulopathies and pulmonary fibrosis, arteriosclerosis, both acute and chronic pain, septic, allergic and post-traumatic shocks, hepatic cirrhosis by hepatorenal syndrome, hypotension, alopecia, or as anticancer or antiangiogenetic agents. 
Oni su posebno pogodni za tretman upalnih, alergijskih, i autoimunih poremećaja kao što je astma i kronični bronhitis, alergijski, vazomotorni i virusni rinitis, kronična opstruktivna plućna bolest (COPD), reumatoidni artritis, kronična upalna bolest crijeva (Crohnova bolest i ulcerativni kolitis), glomerulonefritis, psorijaza, osip, akutni i kronični cistitis; hepatička ciroza, glomerulopatije i plućna fibroza, arteroskleroza, akutna i kronična bol, septički, alergijski 1 postraumatski šokovi i hepatička ciroza od hepatorenalnog sindroma, hipotenzija 1 alopecija ili kao antikancerogeno i antiangiogenetsko sredstvo.
The process of claim 1 wherein the gelling agent is guar gum or locust bean gum. 
Mrvice prema bilo kojem od zahtjeva 1 do 12 gdje je sredstvo za geliranje guar guma ili brašno sjemenke rogača.
Composition according to claim 9, characterized in that said oral form is selected from tablet, capsule, granule, oil bead, solution, suspension, carrier and aerosol, preferably said oral form is tablet, capsule or solution. 
Kompozicija prema patentnom zahtjevu 7, naznačena time da navedeni oralni oblik je odabran od tablete, kapsule, granule, uljane perle, otopine, suspenzije, nosača i aerosola, poželjno navedeni oralni oblik je tableta, kapsula ili otopina.
The method according to claim 1, wherein the compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time, da je on odabran iz skupine koju čine:
A first aspect of the present invention provides a pharmaceutical composition consisting of: 0.02 percent by weight mechlorethamine hydrochloride; 2.00 percent by weight hydroxypropyl cellulose; 0.01 percent by weight edetate disodium dihydrate; 0.05 percent by weight racemic menthol; 0.01 percent by weight butylated hydroxytoluene; 49.91 percent by weight 2-(2-ethoxy-ethoxy)ethanol; 15.27 percent by weight isopropyl alcohol; 17.57 percent by weight propylene glycol; 11.33 percent by weight glycerin; 3.65 percent by weight racemic lactic acid; and 0.18 percent by weight sodium chloride. 
HR P20190551 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak koji se sastoji od: 0.02 težinskih postotaka mekloretamin hidroklorida; 2.00 težinskih postotaka hidroksipropil celuloze; 0.01 težinskih postotaka dinatrijevog edetat dihidrata; 0.05 težinskih postotaka racemičnog mentola; 0.01 težinskih postotaka butiliranog hidroksitoulena; 49.91 težinskih postotaka 2-(2-etoksi-etoksijetanola; 15.27 težinskih postotaka izopropilnog alkohola; 17.57 težinskih postotaka propilen glikola; 11.33 težinskih postotaka glicerina; 3.65 težinskih postotaka racemične mliječne kiseline; i 0.18 težinskih postotaka natrijevog klorida.
Copper ensures effectives against most important wood decay fungi, ethanolamine and carboxylic acid ensures proper fixation and quaternary ammonium compound and boron offers protection against insects, termites and copper tolerant fungi. 
Bakar osigurava djelotvornost protiv najvažnijeg gljivičnog propadanja drva, etanolamin i karboksilna kiselina osiguravaju odgovarajuću fiksaciju i kvaterni amonij i bor pružaju zaštitu od kukaca, termita i gljivica otpornih na bakar.
A compound of formula IV, 
Farmaceutski sastav koji sadrži spoj formule IIB:
treating an intermediate of formula 100 or a salt thereof, where: and R3 together with the nitrogen to which they are attached form a 4-6 membered heterocycloalkyl ring with 1 or 2 nitrogen atoms, which is optionally substituted with 1 or 2 R8; 
je vodik, hidroksi, ili alkil; i R3 je alkil, aminoalkil, alkilaminoalkil, ili dialkilaminoalkil; ili R2 i R3 zajedno s dušikom na koji su oni vezani tvore 3-10 člani heterocikloalkil prsten koji je proizvoljno supstituiran s 1, 2, 3, ili 4 R8; i pri čemu -NR2R3 heterocikloalkil nije morfolinil;
The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein B5 is 
11. Tvar iz patentnog zahtjeva 9, ili njena farmaceutski prihvatljiva sol, pri čemu je Bs
is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl; 
je vodik, halogen, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani heteroalkil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani cikloalkenil, supstituirani ili nesupstituirani heterocikloalkil, supstituirani ili nesupstituirani heterocikloalkenil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani kondenzirani arilni prsten, ili supstituirani ili nesupstituirani heteroaril;
combining bulk aripiprazole and a vehicle to form a primary suspension; 
kombiniranje rasutog aripiprazola i nosača kako bi nastala primarna suspenzija;
It has to be considered that the content of aluminum sulfate is crucial thus dosing of the hydrate requires the corresponding adaption to achieve the desired amount. 
Postupak prema zahtjevu 13, naznačen time da sadržaj aluminijevog sulfata je sve do 5 tež.% bazirano na težini suhe suspenzije.
As a further object, the present invention concerns also the compounds of formula (III) as intermediates of compounds of formula (I). 
Daljnji cilj ovog izuma također su spojevi formule (III), u svojstvu međuprodukata za spojeve formule (I).
compacting the lubricated blend to ribbons of density in a range of 1.1 to 1.2 g/cc and sizing the compacted ribbons using a roller compactor, and wherein the wet granulation process comprises: 
sabijanje ovlažene smjese u trake gustoće u opsegu od 1.1 do 1.2 g/cm3 i formiranje do date veličine sabijenih traka upotrebom valjak kompaktora;
A process for the preparation of a compound of formula I according to claim 1, the process comprising reacting a compound of formula (II) with a compound of formula (III) wherein Ar, R3, R4, R1 and R2 have the meanings described in claim 1. 
Postupak pripreme spoja opće formule I u skladu sa patentnim zahtevom 1, naznačen time da podrazumeva reakciju spoja opće formule (II) I sa spojm opće formule (III) II
A kit comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7, or an activated cytotoxic T lymphocyte according to claim 10, in solution or in lyophilized form; 
(a) posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 4, stanicom u skladu s patentnim zahtjevom 6 ili 7 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 10, u otopini ili u kiofiliziranom obliku; te (b) drugu posudu koja sadrži diluens ili otopinu za rekonstituciju za liofiliziranu formulaciju.
In one embodiment, the anti-myostatin Adnectin of the invention comprises the BC, DE, and FG loops as set forth in SEQ ID NOs: 34, 39, and 75, respectively. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što petlje BC, DE i FG imaju aminokiselinske sljedove iznijete u SEQ ID NO: 34, 39 odnosno 75.
CDR1 is chosen from the group consisting of: 
(i) CDRI se bira iz skupine koju čine:
A is: is selected from methyl, chloro and fluoro, 
R' je odabran od sljedećih: metil, kloro i fluoro, B je:
to 98% (w/w) of a monofunctional acrylate or methacrylate monomer of formula [1]: 
C) 70 do 98 % (težinski) monofunkcionalnog akrilatnog ili metakrilatnog monomera formule [1]: gdje
An electrically heated smoking system according to any preceding claim, wherein at least one of: 
Vlaknasti cementni proizvod, naznačen time što sadrži najmanje jednu profiliranu površinu dobivenu prema bilo kojem od prethodnih patentnih zahtjeva.
The compound according to claim 1, wherein Y represents an oxygen atom. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da Y predstavlja atom kisika.
Beverage according to claim 48, wherein the hydroxyhydrocarbyl residue comprises 1-10 carbon atoms. 
Piće prema zahtjevu 48, naznačeno time, što hidroksihidrokarbilni ostatak sadržava 1-10 atoma ugljika.
excavating a bed (11) designed to accommodate the basin (10), 
- iskapanje ležaja (11) za smještaj osnove (10),
The method of claim 8, wherein a step comprising mechanical grinding of the organisms is carried out before the saponification or the extraction of the cholesterol. 
Postupak u skladu s patentnim zahtjevom 9, 10 ili 11, naznačen time što se prije saponificiranja ili ekstrakcije kolesterola provodi korak mehaničkog mljevenja stanica.
The composition of Aspect 13 or 14, further comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Spoj, njegova farmaceutski prihvatljiva sol ili smjesa prema zahtjevu 5, za uporabu u liječenju bolesti ili stanja izabranih između; emocionalna nestabilnost; o pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropalska bol; bol posredovana simpalikusom; bol povezana s disfunkcijom probavnog suslava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RTT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom.
A twin pack comprising a GPR119 agonist and a DPP-IV inhibitor as a combined preparation for the treatment or prevention of diabetes or a condition related thereto. 
Uporaba u skladu sa zahtjevom 44, naznačena time, da se navedeni lijek koristi za liječenje ili prevenciju dijabetesa tipa 2.
The compound of claim 4, or a tautomer thereof, or pharmaceutically acceptable salt of said compound or tautomer, wherein A is 1,4-cyclohexylene, cyclohex-3-en-1,4-di-yl, tricyclo[3.2.1.0˜2,4˜]octylene-1,3-di-yl or octahydropentalene-1,4-di-yl. 
Spoj u skladu s patentnim zahtjevom 4, ili njegov tautomer, ili farmaceutski prihvatljiva sol navedenog spoja ili tautomera, naznačen time što A je 1,4-cikloheksilen, cikloheks-3-en-1,4-diil, triciklo[3.2.1.0*"Joktilen-1,3-diil ili oktahidropentalen-1,4-diil.
A counter as claimed in any one of claims 4 to 9 wherein said first engagement means is connected to, or integral with, said first ring member. 
Brojač kao što je zahtijevano u patentnom zahtjevu 1 ili 2, gdje su navedena prva sredstva za angažiranje (704) povezana sa, ili integralna sa, navedenim prvim prstenastim članom (201).
A method for providing custom drug and nutritional supplements comprising the following steps: 
Postupak osiguravanja personaliziranog lijeka 1 dodataka prehrani, naznačen time što se sastoji u sljedećim koracima:
Switches: A membrane face overlay with four membrane switches 113, 114, 115, and 116 (see Fig. 
Prekidači: Membranska maska sa četiri membranska prekidača 113, 114, 1151116 (vidjeti sliku 7) bit će nanesena na prednju stranu kutije.
The compound of any one of claims 1-11, wherein R6 is selected from the group consisting of -OH, C1-C6 alkoxy, -OC(O)-C1-C6 alkyl, and -OC(O)phenyl, optionally wherein R6 is -OH; and/or wherein R7 is C1-C6 alkyl, optionally wherein R7 is -CH3. 
Spoj prema bilo kojem od zahtjeva 1-11, pri čemu Rs je odabran od skupine koja se sastoji od -OH, C;-Cg alkoksi, -OC(O)-C1-Cg alkila, 1 -OC(O)fenila, izborno pri čemu Re je -OH; i/ili pri čemu R; je Ci-C4 alkil, izborno pri čemu R; je -CHa.
The device of claim 1, wherein the segregating step has an upstream face on its inlet side that is substantially perpendicular to the portion of the step that defines the downstream portion. 
Uređaj prema jednom od patentnih zahtjeva 1 do 7, pri čemu stupanj odvajanja ima uzvodnu prednju stranu na svojoj ulaznoj strani koja je uspravna na dio stupnja koji definira nizvodni dio.
The method of claim 38, wherein the aqueous pharmaceutical formulation further comprises at least one excipient selected from the group consisting of zinc, m-cresol, glycerol, and polysorbate 20. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 6 do 9, naznačen time da pripravak nadalje sadrži ekscipijente odabrane iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
The pharmaceutical composition of claim 1, wherein the first peptide consists of SEQ ID NO: 7. 
Antitijelo specifično protiv kompleksa MHC/peptid MHC-a s peptidom koji se sastoji od SEQ ID No. 22.
A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of transthyretin (TTR), wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region complementary to a part of a mRNA encoding transthyretin (TTR), wherein said region of complementarity is 19 nucleotides in length, the antisense strand comprises SEQ ID NO:170, and each strand of the dsRNA is 19, 20, 21, 22, 23, or 24 nucleotides in length. 
Dvolančana ribonukleinska kiselina (AsRNA) za inhibiranje ekspresije transtiretina (TTR), naznačena time da (a) navedena dsRNA sadrži sensni lanac i antisensni lanac, te antisensni lanac sadrži regiju komplementarnu s dijelom mRNA koja kodira transtiretin (TTR), pri čemu je navedena regija komplementarnosti duljine 19 nukleotida, te antisensni lanac sadrži SEQ ID NO:170, 1 svaki lanac dsRNA je duljine 19, 20, 21, 22, 23, ili 24 nukleotida; ili
The residue, after addition of 10% aq KHSO4 (100 mL) was further diluted with 100 mL of H2O prior to being extracted 3× with EtOAc. 
Ostatak, poslije dodavanja 10% vodene otopine KHSO4 (100 ml) je dodatno razblažen sa 100 ml H2O prije ekstrakcije 3x sa EtOAc.
The reaction mixture is stirred at 25°C for 5 minutes. 
Reakcijsku smjesu se miješa 5 minuta pri 25%C.
r is zero or an integer from 1 to 3. 
T je nula ili cijeli broj od 1 do 3.
Other cancers that can be treated with a compound of the present invention include endometrial cancer, head and neck cancer, glioblastoma, malignant ascites, and hematopoietic cancers. 
(D) melanoma, seminoma, teratokarcinoma, osteosarkoma, xenoderoma pigmentosum, keratoktantoma, folikularnog karcinoma štitnjače, Kaposijevog sarkoma, raka endometrija, raka glave i vrata, glioblastoma, malignog ascitesa, ili hematopoetskih rakova.
The method of claim 1, wherein the equation comprises the inverse of the product of the concentration of creatinine and the concentration of free SDMA. 
Postupak sukladno zahtjevu 1, naznačen time što jednadžba sadrži inverziju produkta koncentracije kreatinina i koncentracija slobodnog SDMA.
The effect is generally minor over the preferred SDS range. 
Učinak je općenito manji unutar preferiranog opsega SDS.
In the first position, the inlet valve 7 is open allowing liquid 4 from the container 3 to enter the metering chamber 6 . 
U prvom položaju, ulazni ventil 7 je otvoren, što omogućuje da tekućina 4 iz spremnika 3 uđe u odmjernu komoru 6.
A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of the formula or a stereoisomer thereof, and a pharmaceutically acceptable excipient. 
ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, tautomer, stereoizomer ili izotopno označen derivat, pri čemu je: prsten A'' izabran od,,, i;
The composition of any preceding embodiment, wherein the bacterial strain is lyophilised. 
(c) bakterijska vrsta je liofilizirana; i/ili
The composition of claim 11 wherein said pH adjusting agent is bicarbonate, carbonate, sodium hydroxide, calcium hydroxide, potassium hydroxide, tromethamine, or mixtures thereof, preferably sodium bicarbonate. 
Sastav prema zahtjevu 11, naznačeno time da je spomenuti agens prilagodbe pH vrijednosti bikarbonat, karbonat, natrijev hidroksid, kalcijev hidroksid, kalijev hidroksid, trometamin, ili mješavina istih, poželjno natrijev bikarbonat.
A composition for use according to any of claims 9 to 12, wherein the method comprises administering the soluble receptor to a human patient with radiation therapy, chemotherapy, or an antibody against an additional tumor associated antigen. Isolated DNA encoding a soluble FZD receptor, wherein the DNA comprises 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 3, za uporabu prema zahtjevu 5 ili zahtjevu 6, naznačen time, da postupak obuhvaća primjenu na ljudskom pacijentu u vidu davanja topivog receptora zajedno s radijacijskim liječenjem, kemoterapijom ili protutijelom protiv dodatnog antigena povezanog s tumorom.
Object exploration. The object exploration is defined by animals licking, sniffing or touching the object with the forepaws whilst sniffing, but not leaning against, turning around, standing or sitting on the object. 
Predmet istraživanja je određen time što je životinja lizala, njuškala ili dodirivala predmet prednjim šapama za vrijeme njuškanja, ali ne naginjanjem preko, kretanjem oko, stajanjem ili sjedenjem na predmetu.
A composition comprising a first isolated polynucleotide encoding a polypeptide comprising the sequence of SEQ ID NO: 267 and a second isolated polynucleotide encoding a polypeptide comprising the sequence of SEQ ID NO: 265. 
Sastav, naznačen time, da obuhvaća prvi izolirani polinukleotid koji kodira polipeptid koji sadrži sekvencu SEK ID BR: 267 i drugi izolirani polinukleotid koji kodira polipeptid koji sadrži sekvencu SEK ID BR: 265.
In the first reaction step, 7-ethylcamptothecin of formula II is oxidized with hydrogen peroxide in acetic acid under formation of 7-ethylcamptothecin 1-oxide of formula III which in the second reaction step is dissolved-in the solvent system dioxane-acetonitrile-water and the solution is irradiated with UV light in the presence of sulfuric acid to afford the desired 7-ethyl-10-hydroxycamptothecin (see U.S. Pat. 
U prvom koraku 7-etilkamptotecin formule II kojeg se u drugom koraku otapa u sustavu otapala dioksan/acetonitril/voda, a otopinu ozrači UV svjetlom, u prisutnosti sumporne kiseline, kako bi se dobilo željeni 7-etil-10-hidroksikamptotecin (vidjeti dokumente US 4 473 692 i US 4 513 138, te Zhongguo Yaowu Huaxue Zazhi: 11 (4), 238-240, (2001.)).
characterized by the fact that: 
karakteriziran na način:
A pharmaceutical composition comprising ET-743 in combination with a pharmaceutically acceptable carrier, diluent or excipient is claimed in US 5,256,663. 
Farmaceutska smjesa koja sadrži ET-743 u kombinaciji s farmaceutski prihvatljivim nosačem, otapalom ili inertnim puniocem navodi se u US 5,256,663.
A method of inhibiting the replication of influenza viruses in a biological sample, or reducing the amount of influenza viruses in a biological sample, comprising the step of administering to said biological sample an effective amount of a compound as described in any one of claims 1-10. 
Postupak za inhibiciju replikacije virusa gripe u in vitro biološkom uzorku koji sadrži korak primjene na navedeni biološki uzorak efikasne količine spoja formule: [image] ili njegove farmaceutski prihvatljive soli.